Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Psoriasis patients demonstrate reduced dementia risk

Key clinical point: Psoriasis patients had a significantly lower prevalence of dementia compared to controls.

Major finding: The prevalence of dementia in psoriasis patients was 1.6% vs. 1.8% for controls (P < 0.001), and retained significance after controlling for demographics, cardiovascular risk factors, and depression, although the significance among moderate-to-severe psoriasis patients disappeared after controlling for additional factors including metabolic variables, healthcare utilization, and exposure to acitretin and methotrexate.

Study details: The data come from a cross-sectional study of 121,801 psoriasis patients, including 16,947 with moderate-to-severe disease, and 121,802 controls.

Disclosures: The study received no outside funding. Lead author Dr. Kridin had no financial conflicts to disclose.


“This is a somewhat surprising finding. Psoriasis patients tend to be at higher risk for most comorbidities. This is one of the few comorbidities where the risk seems to be lower. In another study about a different neurologic comorbidity, patients with psoriasis onset preceding relapsing-remitting multiple sclerosis had slower progression of disease compared to multiple sclerosis-only patients, as shown by a longer time to second relapse (P < 0.01) and a longer time to significant neurological disability scores (PMID: 28609573). More work needs to be done to further define these 2 neurologic comorbidities and psoriasis.”

Jashin J. Wu, MD

Founder and Course Director, San Diego Dermatology Symposium, June 11-13, 2021

Founder and CEO, Dermatology Research and Education Foundation, Irvine, CA


Kridin K et al. Acta Derm Venereol. 2020 Jul 29. doi: 10.2340/00015555-3595.